New York State Common Retirement Fund
CTMX icon

New York State Common Retirement Fund’s CytomX Therapeutics CTMX Stock Holding History

New York State Common Retirement Fund’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-445
Closed -$1K – 3307
2022
Q2 		$1K Sell
445
-30,158
-99% -$57.7K ﹤0.01% 3334
2022
Q1 		$82K Buy
30,603
+91
+0.3% +$349 ﹤0.01% 3069
2021
Q4 		$132K Sell
30,512
-143
-0.5% -$838 ﹤0.01% 3007
2021
Q3 		$156K Sell
30,655
-18,828
-38% -$101K ﹤0.01% 2995
2021
Q2 		$313K Buy
49,483
+6,483
+15% +$50.5K ﹤0.01% 2825
2021
Q1 		$332K Sell
43,000
-9,127
-18% -$72.2K ﹤0.01% 2651
2020
Q4 		$341K Sell
52,127
-13,900
-21% -$99.3K ﹤0.01% 2529
2020
Q3 		$439K Hold
66,027
– – ﹤0.01% 2268
2020
Q2 		$550K Buy
66,027
+18,483
+39% +$172K ﹤0.01% 2154
2020
Q1 		$365K Sell
47,544
-1,883
-4% -$13.1K ﹤0.01% 2193
2019
Q4 		$411K Sell
49,427
-1,400
-3% -$9.45K ﹤0.01% 2396
2019
Q3 		$375K Buy
50,827
+1,200
+2% +$11.8K ﹤0.01% 2477
2019
Q2 		$557K Sell
49,627
-350
-0.7% -$3.67K ﹤0.01% 2325
2019
Q1 		$537K Sell
49,977
-550
-1% -$8.13K ﹤0.01% 2270
2018
Q4 		$763K Sell
50,527
-1,250
-2% -$18.5K ﹤0.01% 2057
2018
Q3 		$958K Sell
51,777
-5,800
-10% -$132K ﹤0.01% 2116
2018
Q2 		$1.32M Buy
57,577
+10,680
+23% +$273K ﹤0.01% 1941
2018
Q1 		$1.33M Buy
46,897
+4,420
+10% +$126K ﹤0.01% 1858
2017
Q4 		$897K Buy
42,477
+5,577
+15% +$116K ﹤0.01% 2096
2017
Q3 		$670K Buy
36,900
+5,800
+19% +$90.5K ﹤0.01% 2213
2017
Q2 		$482K Buy
31,100
+10,199
+49% +$154K ﹤0.01% 2427
2017
Q1 		$361K Buy
20,901
+1
+0% +$13 ﹤0.01% 2534
2016
Q4 		$230K Hold
20,900
– – ﹤0.01% 2720
2016
Q3 		$328K Hold
20,900
– – ﹤0.01% 2540
2016
Q2 		$213K Buy
20,900
+13,600
+186% +$155K ﹤0.01% 2696
2016
Q1 		$94K Buy
+7,300
New +$101K ﹤0.01% 2940

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

New York State Common Retirement Fund's CTMX Position: Q3 2022 in Review

New York State Common Retirement Fund sold out of CytomX Therapeutics (CTMX) in Q3 2022, closing a stake of 445 shares — an estimated $1K sold.

New York State Common Retirement Fund first reported a position in CTMX in Q1 2016 and held it in 26 quarters. The position peaked at $1.33M in Q1 2018. 84 funds tracked by Wall St. Rank hold CTMX as of Q3 2022.

  • New York State Common Retirement Fund reported no remaining CytomX Therapeutics position as of Q3 2022 after selling out during the quarter.
  • New York State Common Retirement Fund sold 445 CytomX Therapeutics shares in Q3 2022, an estimated $1K.
  • New York State Common Retirement Fund first reported a position in CytomX Therapeutics in Q1 2016 and held it in 26 quarters.
  • New York State Common Retirement Fund's CytomX Therapeutics position peaked at $1.33M in Q1 2018.
  • 84 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2022.

Based on New York State Common Retirement Fund's 13F filing for Q3 2022, filed 8 Nov 2022.